Boundless Bio, Inc.
No SEC Form 4 filings for $BOLD in the last 30 days.
See all $BOLD insider activity →Several biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.
TANG KEVIN purchased 63,969 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.43 ($2.43–$2.44, $0.16M total) across 3 trades over 2026-07-14 to 2026-07-16.
TANG KEVIN purchased 91,585 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.42 ($2.42–$2.48, $0.22M total) across 3 trades over 2026-07-09 to 2026-07-13.
Over the past 7 days, alphai's AI scored 1 news story mentioning BOLD (Boundless Bio, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent BOLD coverage spans insider activity, market movers and financial news.
First‑in‑human data could be a catalyst for valuation.
A 10% owner open-market purchase is a modest bullish signal, but it is not a fundamental catalyst like earnings, guidance, or a deal.
This is an insider open-market purchase disclosed via Form 4, which can modestly support sentiment but is not a fundamental catalyst by itself.
Incremental insider/major-holder buying near the stock’s 52-week high may support momentum positioning.
The filing signals insider accumulation, but it is not a fundamental catalyst like earnings, guidance, or a deal.
alphai scores every news story that mentions BOLD with an AI model for sentiment and relevance, and aggregates insider trades from Boundless Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Several biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.
3 min readTANG KEVIN purchased 63,969 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.43 ($2.43–$2.44, $0.16M total) across 3 trades over 2026-07-14 to 2026-07-16.
2 min readTANG KEVIN purchased 91,585 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.42 ($2.42–$2.48, $0.22M total) across 3 trades over 2026-07-09 to 2026-07-13.
1 min readA roundup of July 8, 2026 insider trades reported major buys in Mission Produce (AVO), where Globalharvest Holdings Venture Ltd bought 650,415 shares for about $8.28M at $12.73 avg, and Boundless Bio (BOLD), where Tang Capital bought 57,210 shares for about $141.9K. Major sells included Rocket Lab (RKLB) CEO Peter Beck selling about $286.4M and Dell (DELL) director Egon Durban/Silver Lake selling about $29.9M.
7 min readTANG KEVIN purchased 57,210 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.48 ($2.46–$2.49, $0.14M total) across 3 trades over 2026-07-06 to 2026-07-08.
2 min readInvesting.com reports US insider trades disclosed Thursday. Buys: JCTC ($25,871; 11,009 shares at $2.35), BGDE ($16.7M Series D at $1,000), HDSN (~764,202 shares for ~$4.48M), BOLD (~$268,880), and COLB ($22,477). Sells: CRWV CEO sold ~$37.7M; EWTX CSO sold ~$7.88M; ALAB director sold ~$5.62M.
6 min readTANG KEVIN purchased 107,463 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.50 ($2.49–$2.54, $0.27M total) across 4 trades over 2026-06-30 to 2026-07-02.
2 min readTANG KEVIN purchased 286,333 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.50 ($2.47–$2.56, $0.71M total) across 6 trades over 2026-06-25 to 2026-06-29.
2 min readBoundless Bio (BOLD) agreed to an all-stock merger with private Serapha Bio; it expects a pre-close cash dividend and plans to trade as Serapha on Nasdaq under “AATD” in Q4 2026. Monopar (MNPR) said its ALXN1840 Wilson disease NDA is on track for mid-2026. Galectin (GALT) reached FDA agreement on key Phase 3 MASH protocol elements; final protocol due Q3 2026.
7 min readBoundless Bio, Inc. (BOLD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 d159021dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: BOUNDLESS BIO, INC.; BOULDER MERGER SUB CORP.; and SERAPHA BIO, INC. Dated as of June 22, 2026 TABLE OF CONTENTS Page Article I. Definitions and Interpretative Provisions 2
4 min read